Kruyt Nyika D, Biessels Geert Jan, de Haan Rob J, Vermeulen Marinus, Rinkel Gabriel J E, Coert Bert, Roos Yvo B W E M
Department of Neurology, Academic Medical Centre, University of Amsterdam. PO Box 22700, 1100 DE Amsterdam, The Netherlands.
Stroke. 2009 Jun;40(6):e424-30. doi: 10.1161/STROKEAHA.108.529974. Epub 2009 Apr 23.
Hyperglycemia may worsen outcome after aneurysmal subarachnoid hemorrhage. We performed a systematic review to investigate the relation between admission hyperglycemia and outcome after aneurysmal subarachnoid hemorrhage.
We included cohort studies or clinical trials of patients with aneurysmal subarachnoid hemorrhage admitted within 72 hours that documented admission glucose levels or the rate of hyperglycemia. Outcome had to be assessed prospectively after 3 or more months. The overall mean glucose level was calculated by weighting for the number of patients included in each study. To calculate the effect size, we pooled the ORs and 95% 95% CIs of poor clinical outcome in patients with or without hyperglycemia.
We searched MEDLINE, EMBASE, Science Citation Index, and the bibliographies of relevant studies. We included 17 studies totaling 4095 patients. The mean admission glucose level was 9.3 mmol/L (range, 7.4 to 10.9 mmol/L; 14 studies, 3373 patients) and the median proportion of patients with hyperglycemia was 69% (range, 29 to 100; 16 studies, 3995 patients; cutoff levels of hyperglycemia, 5.7 to 12.0 mmol/L). The pooled OR (8 studies, 2164 patients) for poor outcome associated with hyperglycemia was 3.1 (95% CI, 2.3 to 4.3). Cutoff points for defining hyperglycemia varied across studies (6.4 to 11.1 mmol/L), but this had no clear effect on the observed OR for poor outcome.
After aneurysmal subarachnoid hemorrhage, admission glucose levels are often high and hyperglycemia is associated with an increased risk of poor clinical outcome. A randomized clinical trial is warranted to study the potential benefit of glycemic control after aneurysmal subarachnoid hemorrhage.
高血糖可能会使动脉瘤性蛛网膜下腔出血后的预后恶化。我们进行了一项系统评价,以研究入院时高血糖与动脉瘤性蛛网膜下腔出血后预后之间的关系。
我们纳入了对在72小时内入院的动脉瘤性蛛网膜下腔出血患者进行的队列研究或临床试验,这些研究记录了入院时的血糖水平或高血糖发生率。必须在3个月或更长时间后对预后进行前瞻性评估。通过对每项研究中纳入的患者数量进行加权计算总体平均血糖水平。为了计算效应量,我们汇总了有或无高血糖患者不良临床结局的OR值和95%可信区间。
我们检索了MEDLINE、EMBASE、科学引文索引以及相关研究的参考文献。我们纳入了17项研究,共4095例患者。平均入院血糖水平为9.3 mmol/L(范围为7.4至10.9 mmol/L;14项研究,3373例患者),高血糖患者的中位数比例为69%(范围为29至100;16项研究,3995例患者;高血糖的截断水平为5.7至12.0 mmol/L)。与高血糖相关的不良结局的汇总OR值(8项研究,2164例患者)为3.1(95%可信区间为2.3至4.3)。不同研究中定义高血糖的截断点有所不同(6.4至11.1 mmol/L),但这对观察到的不良结局OR值没有明显影响。
动脉瘤性蛛网膜下腔出血后,入院时血糖水平通常较高,高血糖与不良临床结局风险增加相关。有必要进行一项随机临床试验,以研究动脉瘤性蛛网膜下腔出血后血糖控制的潜在益处。